In order to obtain the key intermediate of vandetanib,4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline was synthesized from methyl 4-[1-(tert-butoxycarbonyl) piperidin-4-ylmethoxy]-3-methoxybenzoate by ...In order to obtain the key intermediate of vandetanib,4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline was synthesized from methyl 4-[1-(tert-butoxycarbonyl) piperidin-4-ylmethoxy]-3-methoxybenzoate by deprotection,methylation,nitration,reduction,ring formation and substitution reaction in an overall yield of 58%.The structures of the compound and its intermediates were determined by 1H NMR and MS.展开更多
3-（4-Hydroxyphenyl）-4-methyl-6-methoxy-7-hydroxycoumarin （2a） and its analogues with different substituents at the p-position of 3-phenyl group were designed and synthesized as the non-steroidal analogues of 2-met...3-（4-Hydroxyphenyl）-4-methyl-6-methoxy-7-hydroxycoumarin （2a） and its analogues with different substituents at the p-position of 3-phenyl group were designed and synthesized as the non-steroidal analogues of 2-methoxyestradiol （2-ME 1）. The desired compounds were synthesized via a novel and simple route and the effects of specific substituents on their antiangiogenesis activities were investigated with Human umbilical vein endothelial cells （HUVECs） proliferation assays. Preliminary biological screening showed that compounds 2a and 2d （IC50 = 61.0 and 76.7 ktM, respectively） have potential anti-angiogenesis activities. The bulk of the group at the p-position of 3-phenyl group likely play an important role in their activities.展开更多
文摘In order to obtain the key intermediate of vandetanib,4-chloro-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline was synthesized from methyl 4-[1-(tert-butoxycarbonyl) piperidin-4-ylmethoxy]-3-methoxybenzoate by deprotection,methylation,nitration,reduction,ring formation and substitution reaction in an overall yield of 58%.The structures of the compound and its intermediates were determined by 1H NMR and MS.
文摘3-（4-Hydroxyphenyl）-4-methyl-6-methoxy-7-hydroxycoumarin （2a） and its analogues with different substituents at the p-position of 3-phenyl group were designed and synthesized as the non-steroidal analogues of 2-methoxyestradiol （2-ME 1）. The desired compounds were synthesized via a novel and simple route and the effects of specific substituents on their antiangiogenesis activities were investigated with Human umbilical vein endothelial cells （HUVECs） proliferation assays. Preliminary biological screening showed that compounds 2a and 2d （IC50 = 61.0 and 76.7 ktM, respectively） have potential anti-angiogenesis activities. The bulk of the group at the p-position of 3-phenyl group likely play an important role in their activities.
